What is the current Price Target for the Carisma Therapeutics stock?

The average Carisma Therapeutics target price is $1.02. This is 1,493.75% higher than the current stock price. The highest price target is 1,540.63%, the lowest is 1,478.13%. 3 Analysts have issued a price target Carisma Therapeutics 2026 .

How high will the Carisma Therapeutics stock rise?

No reliable answer can be given as to how high the Carisma Therapeutics stock will rise. The performance of stocks, including the Carisma Therapeutics stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Carisma Therapeutics stock today?

The performance of Carisma Therapeutics stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Carisma Therapeutics stock fall?

The decline in Carisma Therapeutics stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Carisma Therapeutics Forecast, price target & analysts

$0.06

14.29% day before yesterday

NYSE, Nov 14, 09:59 pm CET

ISIN

US14216R1014

Symbol

CARM

Reports

Quarter | Annual

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Carisma Therapeutics Target price 2025 - Analyst rating & recommendation

Carisma Therapeutics Classifications & Recommendation:

Buy

75%

Hold

25%

Carisma Therapeutics Price Target

Target Price	$1.02
Price	$0.06
Potential	1,493.75% register free of charge
Number of Estimates	3

	3 Analysts have issued a price target Carisma Therapeutics 2026 . The average Carisma Therapeutics target price is $1.02. This is 1,493.75% register free of charge higher than the current stock price. The highest price target is $1.05 1,540.63% register free of charge , the lowest is $1.01 1,478.13% register free of charge .
	A rating was issued by 8 analysts: 6 Analysts recommend Carisma Therapeutics to buy, 2 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Carisma Therapeutics stock has an average upside potential 2026 of 1,493.75% register free of charge . Most analysts recommend the Carisma Therapeutics stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-1.46	-0.70
	43.63%	52.05%
P/E		negative

4 Analysts have issued a Carisma Therapeutics forecast for earnings per share. The average Carisma Therapeutics EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-1.46	43.63%
2025	$-0.70 52.05% Unlock
2026	$-0.53 24.29% Unlock
2027	$-0.45 15.09% Unlock
2028	$-0.43 4.44% Unlock
2029	$-0.43 0.00% Unlock
2030	$-2.23 418.60% Unlock
2031	$-1.96 12.11% Unlock
2032	$-1.69 13.78% Unlock

Current	-0.05	91.79%
2025	-0.09 66.05% Unlock
2026	-0.12 33.33% Unlock
2027	-0.14 16.67% Unlock
2028	-0.15 7.14% Unlock
2029	-0.15 0.00% Unlock
2030	-0.03 80.00% Unlock
2031	-0.03 0.00% Unlock
2032	-0.04 33.33% Unlock

Carisma Therapeutics...

Current Carisma Therapeutics Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
D. Boral Capital	Locked ➜ Locked	Locked	Aug 08 2025
D. Boral Capital	Locked ➜ Locked	Locked	Apr 01 2025
D. Boral Capital	Locked ➜ Locked	Locked	Jan 17 2025
D. Boral Capital	Locked ➜ Locked	Locked	Jan 13 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Dec 16 2024
Baird	Locked ➜ Locked	Locked	Dec 12 2024
D. Boral Capital	Locked ➜ Locked	Locked	Dec 12 2024

Analyst Rating	Date
Locked D. Boral Capital: Locked ➜ Locked	Aug 08 2025
Locked D. Boral Capital: Locked ➜ Locked	Apr 01 2025
Locked D. Boral Capital: Locked ➜ Locked	Jan 17 2025
Locked D. Boral Capital: Locked ➜ Locked	Jan 13 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Dec 16 2024
Locked Baird: Locked ➜ Locked	Dec 12 2024
Locked D. Boral Capital: Locked ➜ Locked	Dec 12 2024

Discover more stocks with a high price target

Novo Nordisk 50.02%

Adidas 49.23%

Meta Platforms (Facebook) 46.44%

Coinbase Global, Inc. 45.10%

TUI 44.85%

Deutsche Telekom 42.29%

BYD 35.82%

BioNTech SE - ADR 35.06%

Walt Disney 33.04%

Adyen 32.90%

Rheinmetall 29.94%

Alibaba Group Holding Ltd 28.66%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now